At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
hCGdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study the Effects of Intrauterine Flushing With Low Dose Human Chorionic Gonadotropin on Ultrasound Parameter and Immunological Marker of Endometrial Receptivity of Infertile Female Undergoing ICSI Cycle
In Brief
A Phase 4 clinical trial evaluating hCG for Female Infertility. Completed, enrolled 90 participants across 1 site.
Detailed Summary
a number of infertile women who were prepared for ICSI and immediately post ova pick up intrauterine flushing with human chorionic gonadotropin was done to study the effect of this drug on ICSI outcome and ultrasound parameter.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFemale Infertility
CountriesIraq
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
Enrollment StartOct 2022
Primary CompletionJan 2024
Study CompletionApr 2024
First PostedNov 2024
TodayJul 2026
First PostedNov 12, 2024
Enrollment StartOct 23, 2022
Primary CompletionJan 23, 2024
Study CompletionApr 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 1.6 years ago
Interventions
hCGdrug
observe hCG effect on endometrial receptivity